EU/3/17/1940

About

On 12 October 2017, orphan designation (EU/3/17/1940) was granted by the European Commission to Novo Nordisk A/S, Denmark, for concizumab for the treatment of haemophilia B.

Key facts

Active substance
Concizumab
Disease / condition
Treatment of haemophilia B
Date of first decision
12/10/2017
Outcome
Positive
EU designation number
EU/3/17/1940

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Novo Nordisk A/S
Novo Alle 1
2880 Bagsvaerd
Denmark
Tel. +45 4444 8888
E-mail: webmasters@novonordisk.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating